Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2024-02-27 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'YEAR END REPORT 2023' and contains comprehensive financial statements, including net sales, operating profit, cash flow, and balance sheet data for the full fiscal year 2023. It includes a CEO review, detailed breakdowns of expenses (R&D, marketing, administrative), and a 'Going Concern' assessment. As it covers a full fiscal year and provides substantive financial data and analysis, it is classified as an Interim/Quarterly Report (IR) in the context of this database, as it serves as the primary financial reporting document for the period. Q4 2023
2024-02-27 English
Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority
Regulatory Filings Classification · 1% confidence The document is a press release dated February 23, 2024, announcing that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of Pepaxti (melflufen). This is a specific corporate event announcement regarding market access and pricing negotiations for a drug. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A). It is a specific regulatory/market access update. Since it details a specific regulatory/pricing step for a drug, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate announcement that doesn't fit the other specific categories like DIRS, DIV, or CAP. It is too detailed to be a simple Report Publication Announcement (RPA) which usually just announces the release of another document.
2024-02-23 English
Oncopeptides får positiv rekommendation av Pepaxti från den spanska prismyndigheten
Regulatory Filings Classification · 1% confidence The document is a press release from Oncopeptides AB dated February 23, 2024, announcing a positive pricing recommendation for their drug Pepaxti from the Spanish pricing authority (CIPM). It discusses regulatory steps, market access, and future communication plans (mentioning the upcoming earnings release on Feb 27th). The content is a specific corporate announcement regarding regulatory/pricing progress, not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). It is a general regulatory/corporate update. Since it details a specific regulatory/pricing milestone and is structured as a formal announcement, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory disclosure under EU Market Abuse Regulation, or potentially a specialized announcement if one existed. Given the provided definitions, RNS serves as the best fit for a general, material regulatory announcement that isn't a standard financial report or management change.
2024-02-23 Swedish
Oncopeptides ensures five years extended market exclusivity for Pepaxti in Europe
Regulatory Filings Classification · 1% confidence The document is a short press release dated February 15, 2024, announcing an extension of market exclusivity (SPC) for the drug Pepaxti in Europe until 2037. It contains key business updates, quotes from the CEO, and contact information. Crucially, it mentions that this information is made public pursuant to the EU Market Abuse Regulation and refers to a future Q4 2023 report presentation. The document length is short (3678 chars) and it functions as an immediate regulatory disclosure of a material event (patent/exclusivity extension). This type of announcement, which is not a full financial report (10-K, IR) or a specific management/governance filing, fits best under the general 'Regulatory Filings' category (RNS) as a mandatory disclosure under market abuse rules, or potentially a Capital/Financing Update (CAP) if the exclusivity extension is viewed as a major asset value change, but RNS is the most appropriate catch-all for mandatory, non-standard disclosures under EU regulations. Given the context of EU Market Abuse Regulation disclosure, RNS (Regulatory Filings) is the most suitable classification for this type of immediate, material, non-periodic announcement.
2024-02-15 English
Oncopeptides säkerställer förlängd marknadsexklusivitet för Pepaxti i Europa med fem år
Regulatory Filings Classification · 1% confidence The document is a press release dated February 15, 2024, announcing that Oncopeptides AB has secured a five-year extension of market exclusivity for its drug Pepaxti in Europe until 2037 via a Supplementary Protection Certificate (SPC). It details the financial implications and mentions that further comments will be made during the Q4 2023 report presentation. The text explicitly states, "Denna information är sådan information som Oncopeptides är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." This indicates a mandatory regulatory disclosure regarding a significant business event (patent/exclusivity extension). Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific transaction report (like DIRS or POS), and it is a formal announcement required by regulation, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for mandatory, non-standard disclosures, or potentially a Capital/Financing Update (CAP) due to the direct impact on market potential (SEK 1.5 billion/year). Given the nature of the announcement—a legal/patent status update impacting commercial rights—RNS is the most appropriate general regulatory filing category when a more specific one like 'TAR' (M&A) or 'CAP' (financing) doesn't perfectly align with the core subject matter (patent extension). However, because it is a formal announcement of a material event required under EU market abuse regulation, RNS is the safest classification.
2024-02-15 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT, JANUARI-SEPTEMBER 2023' (Interim Report, January-September 2023). It contains comprehensive financial statements, including income statements, cash flow summaries, and detailed management commentary on business performance, research and development, and financial position for the specified period. It is a substantive financial report rather than an announcement or certification. 9M 2023
2023-11-08 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.